October has been a busy month for Idiopathic Pulmonary Fibrosis (IPF) with ‘World IPF Week 2014’ and the FDA recent approval of two new therapeutics, Ofev (nintedanib) and Esbriet® (pirfenidone), for treating this rare disease.
With a growing interest by the industry to develop new healthcare solutions in the area, we have expanded the Epiomic™ database to include IPF in the Lung, Respiratory & Breathing Disorders category.
IPF is a chronic & progressive fibrotic lung disease of unknown cause which occurs primarily in adults over the age of 50; only 35 people in the UK under the age of 50 have a diagnosis of IPF in 2014.
To fully understand this disease area, we have segmented the total eligible population by a number of factors such as GAP stage and disease state as well as significant co-morbid conditions such as the presence of gastric reflux and pulmonary hypertension. Continuous variables for lung function, such as FVC and FEV1/FVC ratio, are also included to further segment the population. This will be important for products looking to address a specific sub-population and in situations requiring a forecast or product valuation.
With some considerable variations between the different countries with this disease, it will be important for users to look across all 8 markets available to accurately assess the potential for their product.
Almost 40% of patients who are diagnosed with IPF will have a comorbid lung condition such as COPD.